The Manufacturers Life Insurance Company Makes New $1.20 Million Investment in PROCEPT BioRobotics Corporation $PRCT

Key Points

• The Manufacturers Life Insurance Company initiated a position of 53,295 PROCEPT BioRobotics shares worth approximately $1.2 million. Institutional investors collectively own 89.46% of the company.
• PROCEPT reported quarterly revenue of $94.5 million, up 19.3% year over year, but its $0.47 loss per share narrowly missed estimates. The company remains unprofitable, with analysts expecting a full-year loss of $1.67 per share.
• Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $25.09. The company also faces securities litigation alleging it concealed weakness in handpiece sales and excess customer inventory, though the allegations remain unproven.

The Manufacturers Life Insurance Company bought a new position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 53,295 shares of the company's stock, valued at approximately $1,203,000. The Manufacturers Life Insurance Company owned about 0.09% of PROCEPT BioRobotics at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. BlackRock Inc. bought a new position in shares of PROCEPT BioRobotics in the second quarter worth about $109,961,000. Prosight Management LP boosted its position in PROCEPT BioRobotics by 1,692.4% in the 4th quarter. Prosight Management LP now owns 1,380,000 shares of the company's stock valued at $43,415,000 after buying an additional 1,303,009 shares during the period. Alliancebernstein L.P. boosted its position in PROCEPT BioRobotics by 58.6% in the 3rd quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company's stock valued at $122,052,000 after buying an additional 1,262,928 shares during the period. T. Rowe Price Investment Management Inc. grew its stake in PROCEPT BioRobotics by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company's stock worth $102,919,000 after acquiring an additional 1,218,815 shares in the last quarter. Finally, William Blair Investment Management LLC bought a new position in PROCEPT BioRobotics in the 2nd quarter worth about $16,020,000. 89.46% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: The stock’s increase suggests investors may be treating the latest announcements as repetitive legal notices rather than a new deterioration in the company’s business. The reports did not announce a judgment, settlement, regulatory penalty, or additional financial charge.
• Neutral Sentiment: Multiple firms—including Kaplan Fox class action deadline Kaplan Fox, Hagens Berman investor deadline Hagens Berman, and Rosen Law investor deadline Rosen Law—reminded investors that September 22, 2026 is the deadline to seek lead-plaintiff status. The proposed class covers purchases made from February 28, 2024, through February 25, 2026.
• Negative Sentiment: The lawsuit alleges that PROCEPT made misleading statements or failed to disclose repeated weakness in unit handpiece sales and excess customer inventory, allegedly caused in part by late-quarter bulk discounts. Law firms say these issues contributed to a substantial stock decline, including an approximately 18% drop cited in the filings. The allegations remain unproven, but continued litigation could increase costs, management distraction, and investor uncertainty. Hagens Berman securities fraud lawsuit

PROCEPT BioRobotics Stock Performance

Shares of PROCEPT BioRobotics stock opened at $22.76 on Friday. The company has a market capitalization of $1.30 billion, a PE ratio of -11.73 and a beta of 0.91. The company has a 50-day simple moving average of $20.35 and a two-hundred day simple moving average of $23.69. PROCEPT BioRobotics Corporation has a one year low of $16.67 and a one year high of $41.51. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.35 and a current ratio of 6.55.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.01). The firm had revenue of $94.50 million during the quarter, compared to the consensus estimate of $92.77 million. PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The firm's quarterly revenue was up 19.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.35) earnings per share. Research analysts expect that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current fiscal year.

Insider Transactions at PROCEPT BioRobotics

In other news, CEO Larry Wood purchased 23,900 shares of the business's stock in a transaction on Friday, August 7th. The shares were acquired at an average cost of $20.85 per share, with a total value of $498,315.00. Following the completion of the acquisition, the chief executive officer owned 23,900 shares of the company's stock, valued at $498,315. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 1,000 shares of company stock valued at $28,480 over the last 90 days. 4.00% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts have recently weighed in on PRCT shares. TD Cowen decreased their price target on shares of PROCEPT BioRobotics from $34.00 to $28.00 and set a "buy" rating for the company in a research note on Wednesday, August 5th. Weiss Ratings reissued a "sell (e+)" rating on shares of PROCEPT BioRobotics in a research note on Friday, July 17th. Piper Sandler reduced their price objective on PROCEPT BioRobotics from $35.00 to $25.00 and set an "overweight" rating on the stock in a report on Wednesday, August 5th. Citigroup cut PROCEPT BioRobotics to a "hold" rating in a report on Thursday, July 2nd. Finally, Wells Fargo & Company downgraded PROCEPT BioRobotics from an "overweight" rating to an "equal weight" rating and set a $19.00 price target on the stock. in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $25.09.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company's technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company's flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.

Want to see what other hedge funds are holding PRCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.